RT Journal Article
SR Electronic
T1 Clinical influence of exercise therapy on sarcopenia in patients with chronic pancreatitis: a study protocol for a randomised controlled trial
JF BMJ Open Gastroenterology
FD BMJ Publishing Group Ltd
SP e000190
DO 10.1136/bmjgast-2017-000190
VO 5
IS 1
A1 Kazunori Yoh
A1 Hiroki Nishikawa
A1 Hirayuki Enomoto
A1 Yoshinori Iwata
A1 Akio Ishii
A1 Yukihisa Yuri
A1 Noriko Ishii
A1 Yuho Miyamoto
A1 Kunihiro Hasegawa
A1 Chikage Nakano
A1 Ryo Takata
A1 Takashi Nishimura
A1 Nobuhiro Aizawa
A1 Yoshiyuki Sakai
A1 Naoto Ikeda
A1 Tomoyuki Takashima
A1 Hiroko Iijima
A1 Shuhei Nishiguchi
YR 2018
UL http://bmjopengastro.bmj.com//content/5/1/e000190.abstract
AB Introduction and purpose Chronic pancreatitis (CP) involves progressive inflammatory changes to the pancreas and can lead to permanent structural damage and impairment of both endocrine and exocrine functions. Current reports highlight a rise in the incidence and prevalence of CP. However, there is limited data currently available concerning patients with CP undergoing exercise therapy (ET). We aim to prospectively examine the influence of ET on sarcopenia in patients with CP.Methods and analysis A detailed evaluation of the nutritional condition and the daily physical activities of each participant will be conducted prior to entering the study. Our patients will be randomly allocated to either: (1) the ET group or (2) the control group. In the ET group, our patients with CP will receive nutritional guidance once a month. The patients with CP will also be instructed to perform exercises with > 3 metabolic equivalents (mets; energy consumption in physical activities/resting metabolic rate) for 60 min/day and to perform exercises >23 mets/week. The primary end point will be an improvement in sarcopenia, defined as an increase in muscle mass and muscle strength, at 3 months postrandomisation. A comparison of the amelioration of sarcopenia in the two groups will be undertaken.Ethics and dissemination The Institutional Review Board at Hyogo College of Medicine approved this study protocol (approval no. 2766). Final data will be publicly announced. A report releasing the study results will be submitted for publication to an appropriate journal.Trial registration number UMIN000029263; Pre-results. No patient is registered at the submission of our manuscript.